Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study

Scott W Woods, Hal Morgenstern, John R Saksa, Barbara C Walsh, Michelle C Sullivan, Roy Money, Keith A Hawkins, Ralitza V Gueorguieva, William M Glazer, Scott W Woods, Hal Morgenstern, John R Saksa, Barbara C Walsh, Michelle C Sullivan, Roy Money, Keith A Hawkins, Ralitza V Gueorguieva, William M Glazer

Abstract

Objective: Most previous studies of the incidence of tardive dyskinesia with atypical antipsychotics compared with conventional antipsychotics have not had tardive dyskinesia as their primary focus. The current study aimed to compare the incidence of tardive dyskinesia with atypical vs conventional antipsychotics using methods similar to those from a previous prospective cohort study at our site in the 1980s.

Method: Three hundred fifty-two initially tardive dyskinesia-free psychiatric outpatients (diagnosed at baseline using the Structured Clinical Interview for DSM-IV) were examined for a new diagnosis of tardive dyskinesia (using the Abnormal Involuntary Movement Scale and Glazer-Morgenstern criteria) every 6 months for up to 4 years at a community mental health center. At baseline, subjects were receiving conventional antipsychotics only (23%), atypicals only (64%), or both (14%). Only 26 subjects had never received conventional antipsychotics. Baseline evaluations were conducted from November 2000 through May 2003. Follow-ups were conducted through February 2005.

Results: Compared with subjects treated with conventional antipsychotics alone since the previous visit, the adjusted tardive dyskinesia incidence rate-ratio for subjects treated with atypical antipsychotics alone was 0.68 (95% CI, 0.29-1.64). The incidence and prevalence of tardive dyskinesia was similar to previous findings at this site in the 1980s.

Conclusions: The incidence of tardive dyskinesia with recent exposure to atypical antipsychotics alone was more similar to that for conventional antipsychotics than in most previous studies. Despite high penetration of atypical antipsychotics into clinical practice, the incidence and prevalence of tardive dyskinesia appeared relatively unchanged since the 1980s. Clinicians should continue to monitor for tardive dyskinesia, and researchers should continue to pursue efforts to treat or prevent it.

Conflict of interest statement

Declaration of Interest

Dr. Woods acknowledges receipt of investigator-initiated grant support from Bristol Myers-Squibb, Eli Lilly, Janssen, and UCB Pharma and advisory board honoraria from Otsuka and Schering-Plough. Dr. Glazer acknowledges receipt of consultant fees from AstraZeneca, Eli Lilly, and Pfizer and speakers’ bureau honoraria from Eli Lilly.

Copyright 2010 Physicians Postgraduate Press, Inc.

References

    1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.
    1. Woods SW. Olanzapine and tardive dyskinesia. Br J Psychiatry. 1999;175:391–392.
    1. Morgenstern H, Glazer WM, Gibowski LD, et al. Predictors of tardive dyskinesia: Results of a cross sectional study in an outpatient population. J Chron Dis. 1987;40:319–327.
    1. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723–733.
    1. Branch PR. Abnormal involuntary movement scale (AIMS) Early Clin Drug Eval Unit Intercom. 1975;4:3–6.
    1. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133–139.
    1. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter] Arch Gen Psychiatry. 1982;39:486–487.
    1. Cicchetti DV, Showalter D. A computer program for determining the reliability of dimensionally scaled data when the numbers and specific sets of examiners may vary at each assessment. Ed Psychol Meas. 1988;48:717–720.
    1. Glazer WM, Moore DC. A tardive dyskinesia clinic in a mental health center. Hosp Community Psychiatry. 1981;32:572–574.
    1. Am Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry. 1997;154:1–63.
    1. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667.
    1. Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27:144–150.
    1. Schooler NR, Levine J. Initiation of long-term pharmacotherapy in schizophrenia -Dosage and side-effect comparisons between oral and depot fluphenazine. Pharmakopsychiatrie Neuro-Psychopharmakologie. 1976;9:159–169.
    1. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15:111–117.
    1. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition, January 1995 FINAL, (SCID-I/P Version 2.0) New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
    1. Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia - 5-year data from a prospective study. Psychopharmacol Bull. 1984;20:387–389.
    1. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry. 1996;53:313–319.
    1. Morgenstern H, Glazer WM, Doucette JT. Handedness and the risk of tardive dyskinesia. Biol Psychiatry. 1996;40:35–42.
    1. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756–765.
    1. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurology. 1972;27:426–430.
    1. Chouinard G, Annable L, Rosschouinard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia - Factors predicting appearance of new cases. J Clin Psychopharmacol. 1988;8:S21–S26.
    1. Woerner MG, Alvir JMJ, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry. 1998;155:1521–1528.
    1. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Austral N Z J Psychiatry. 2004;38:445–449.
    1. van Os J, Walsh E, van Horn E, et al. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group Acta Psychiatr Scand. 2000;101:300–306.
    1. Caligiuri MP, Lacro JP, Rockwell E, et al. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry. 1997;171:148–153.
    1. Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Academy Child Adol Psychiatry. 1997;36:835–843.
    1. Wegner JT, Kane JM, Weinhold P, et al. Cognitive Impairment in Tardive-Dyskinesia. Psychiatry Res. 1985;16:331–337.
    1. Emsley R, Turner HJ, Oosthuizen PP, et al. Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates. Schizophr Res. 2005;75:35–44.
    1. Pappadopulos E, Goldman R, Bates J, et al. Neuropsychological abnormalities precede the onset of tardive dyskinesia (abstract) J Int Neuropsychol Soc. 1997;3:3–4.
    1. van Harten PN, Hoek HW, Matroos GE, et al. Evidence that lithium protects against tardive dyskinesia: the Curacao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol. 2008;18:152–155.
    1. Diehl A, Reinhard I, Schmitt A, et al. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. Eur Psychiatry. 2008 (epub ahead of print)
    1. The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Cochrane Collaboration; 2008.
    1. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999;174:23–30.
    1. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. NEJM. 2002;346:16–22.
    1. Dossenbach MRK, Folnegovic-Smalc V, Hotujac L, et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:311–318.
    1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM. 2005;353:1209–1223.
    1. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the Eur Schizophrneia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry. 2005;66:1130–1133.
    1. Dossenbach M, Arango-Davila C, Ibara HS, et al. Response and relapse in patients with schizophrenia treated with olanzapine, quetiapine, risperidone, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. J Clin Psychiatry. 2005;66:1021–1030.
    1. Gharabawi GM, Bossie CA, Zhu Y. New onset tardive dyskinesia in patients with first episode psychosis receiving risperidone or haloperidol. Am J Psychiatry. 2006;163:938–939.
    1. Miller DD, Eudicone JM, Pikalov A, et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry. 2007;68:1901–1906.
    1. Gaebel W, Riesbeck M, Wolwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-Year results of a randomized controlled trial within the German research network on schizophrenia. J Clin Psychiatry. 2007;68:1763–1774.
    1. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–598.
    1. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8:52S–56S.
    1. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54:327–330.
    1. Bunker MT, Sommi RW, Stoner SC, et al. Longitudinal analysis of abnormal involuntary movements in long- term clozapine-treated patients. Psychopharmacol Bull. 1996;32:699–703.
    1. Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: A cautionary study. Am J Psychiatry. 1987;144:1148–1153.
    1. Hansen TE, Glazer WM, Moore DC. Tremor and tardive dyskinesia. J Clin Psychiatry. 1986;47:461–464.
    1. Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med. 1989;19:133–144.
    1. Munetz MR, Cornes CL. Distinguishing akathisia and tardive dyskinesia: a review of the literature. J Clin Psychopharmacol. 1983;3:343–350.
    1. Sachdev P. Akathisia and Restless Legs. Cambridge, UK: Cambridge University Press; 1995.
    1. Fahn S. Tardive dyskinesia may be only akathisia. NEJM. 1978;299:202–203.
    1. Crane GE. Neuroleptics and their long-term side effects on the central nervous system. In: Bristol Devaugh-Geiss J., editor. Tardive Dyskinesia and Related Involuntary Movement Disorders. John Wright PSG, Inc; 1982. pp. 71–84.
    1. Modestin J, Stephan PL, Erni T, et al. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res. 2000;42:223–230.
    1. Halliday J, Farrington S, MacDonald S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20 year review. Br J Psychiatry. 2002;181:422–427.
    1. Ross DE, Thomas M, Booth M, et al. Rate of tardive dyskinesia in hospitalized patients. Am J Psychiatry. 2005;162:816.
    1. Marshall DL, Hazlet TK, Gardner JS, et al. Neuroleptic drug exposure and incidence of tardive dyskinesia: A records-based case-control study. J Manag Care Pharm. 2002;8:259–265.
    1. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2007;257:169–172.
    1. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69–77.
    1. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry. 2004;161:700–706.
    1. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut’s public mental health system: Rates of changing medications and prescribing styles. Schizophr Bull. 2002;28:17–29.
    1. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004;65:1377–1388.
    1. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry. 2003;64:984–989.
    1. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry. 1999;60:425–426.
    1. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54:55–59.
    1. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia - Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325–329.
    1. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull. 2000;26:451–457.
    1. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004;11:313–327.
    1. Goff DC, Freudenreich O. Polypharmacy in schizophrenia: does anyone truly benefit? Int J Neuropsychopharmacol. 2004;7:109–111.
    1. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry. 2006;163:1316–1318.
    1. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154:1248–1254.
    1. Beasley CM. Author’s reply. Br J Psychiatry. 1999;175:392.
    1. Mahmoud R. TD assessment procedures for Csernansky et al (NEJM 2002;346:16–22) personal communication. Jun 7, 2006.
    1. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33–43.
    1. Haro JM, Edgell ET, Jones PB, et al. The Eur Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment. Acta Psychiatrica Scandinavica. 2003;107:222–232.
    1. Haro JM, Edgell ET, Frewer P, et al. The Eur Schizophrenia Outpatient Health Outcomes Study: Baseline findings across country and treatment. Acta Psychiatrica Scandinavica. 2003;107:7–15.
    1. Tenback DE. Proportion of patients with TD at 6 months who did not have TD at baseline. Personal communication re Tenback et al (J Clin Psychiatry 2005;66:1130–1133) to Woods, S.W. Oct 16, 2005.
    1. Dossenbach M, Erol A, Kessaci ME, et al. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65:312–321.
    1. Kasper S, Lowry AJ, Hodge A, et al. Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 2006;81:139–143.
    1. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry. 2005;162:947–953.
    1. Rabinowitz J. TD rater training procedures for Schooler et al (Am J Psychiatry 2005;162,947–953) personal communication to Woods, S.W. Jun 15, 2006.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren